Alexion Pharma (ALXN) Tops Q1 EPS by 20c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Pharma (ALXN) Reports Positive CHMP Opinion for ULTOMIRIS (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
April 26, 2019 11:01 AM EDTAlexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for ULTOMIRIS® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks. The recommended indication is for the treatment of adult patients... More
